CDK2 Inhibition with BLU-222 in Combination with Ribociclib Demonstrates Robust Antitumor Activity in Pre-Clinical Models of CDK4/6 Inhibitor-Naive and -Resistant HR+/HER2-breast Cancer
CANCER RESEARCH（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined